Skip to content

A Prospective Study on Clinical Effectiveness After SMILE Versus SMILE Xtra in Myopia

A Prospective Study on Clinical Effectiveness After SMILE Versus SMILE Xtra in Myopia

Status
Recruiting
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT06973278
Enrollment
200
Registered
2025-05-15
Start date
2023-02-01
Completion date
2027-02-01
Last updated
2025-05-15

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Myopia

Brief summary

To evaluate the clinical efficacy and refractive stability of SMILE Xtra compared to SMILE in patients with myopia

Interventions

PROCEDURESMILE

Small Incision Lenticule Extraction

PROCEDURESMILE Xtra

Small Incision Lenticule Extraction combined with Corneal Cross-linking (SMILE Xtra)

Sponsors

Shanghai Zhongshan Hospital
Lead SponsorOTHER

Study design

Allocation
NON_RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
NONE

Eligibility

Sex/Gender
ALL
Age
18 Years to 50 Years
Healthy volunteers
No

Inclusion criteria

1. Age between 18 and 50 years. 2. High myopia with a manifest refraction spherical equivalent (MRSE) - 6.00D~-10.00D and refractive changes within ± 0.50D in the past two years; 3. Best corrected distance visual acuity (CDVA) ≥ 20/25. 4. Preoperative refractive status is stable (myopia progression not exceeding 0.50D per year for at least 2 years). 5. Predicted residual stromal thickness (RST) ≥ 250μm after lenticule removal. 6.Soft contact lenses discontinued for at least 1 week, rigid contact lenses for at least 3 weeks, and orthokeratology lenses for at least 3 months.

Exclusion criteria

1. The presence of other eye diseases: keratoconus or suspected keratoconus, active keratoconjunctivitis, severe dry eye, glaucoma, retinal diseases such as retinal tears or macular degeneration, etc., 2. The presence of significant corneal scarring or cataracts affects observation. 3. Systemic diseases such as active systemic inflammation, connective tissue diseases, other conditions that prevent

Design outcomes

Primary

MeasureTime frame
visual acuity1 week, 1 month, 6 months, 12 months,24 months and 36 months

Countries

China

Contacts

Primary ContactCong Jing
lucky_congjing@163.com17269769976

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026